Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 594

1.

Effectiveness of antiretroviral treatment in a South African program: a cohort study.

Fairall LR, Bachmann MO, Louwagie GM, van Vuuren C, Chikobvu P, Steyn D, Staniland GH, Timmerman V, Msimanga M, Seebregts CJ, Boulle A, Nhiwatiwa R, Bateman ED, Zwarenstein MF, Chapman RD.

Arch Intern Med. 2008 Jan 14;168(1):86-93. doi: 10.1001/archinternmed.2007.10.

PMID:
18195200
[PubMed - indexed for MEDLINE]
2.

Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.

Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, Vlok WJ, Mntambo M, Thomas M, Nixon K, Holst HL, Karim QA, Rollins NC, Coovadia HM, Giddy J.

BMC Pediatr. 2007 Mar 17;7:13.

PMID:
17367540
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.

Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR 3rd; Pediatric AIDS Clinical Trials Group 219/219C Study Team.

Clin Infect Dis. 2008 Feb 15;46(4):507-15. doi: 10.1086/526524.

PMID:
18199042
[PubMed - indexed for MEDLINE]
Free Article
4.

Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.

Lohse N, Kronborg G, Gerstoft J, Larsen CS, Pedersen G, Pedersen C, Sørensen HT, Obel N.

Clin Infect Dis. 2006 Jan 1;42(1):136-44. Epub 2005 Nov 30.

PMID:
16323104
[PubMed - indexed for MEDLINE]
Free Article
5.

Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.

Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS.

Ann Intern Med. 2003 Nov 18;139(10):810-6.

PMID:
14623618
[PubMed - indexed for MEDLINE]
6.

Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.

Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, Sterling TR.

J Infect Dis. 2004 Sep 15;190(6):1046-54. Epub 2004 Aug 17.

PMID:
15319852
[PubMed - indexed for MEDLINE]
Free Article
7.

Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes.

Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, Mtonga V, Reid S, Cantrell RA, Bulterys M, Saag MS, Marlink RG, Mwinga A, Ellerbrock TV, Sinkala M.

JAMA. 2006 Aug 16;296(7):782-93.

PMID:
16905784
[PubMed - indexed for MEDLINE]
8.

Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.

Lapadula G, Torti C, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Di Pietro M, Migliorino G, Ouiros-Roldan E, Ladisa N, Sighinolfi L, Costarelli S, Carosi G; Italian MASTER Cohort.

Antivir Ther. 2007;12(6):941-7.

PMID:
17926648
[PubMed - indexed for MEDLINE]
9.

Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy.

Hung CC, Chen MY, Hsiao CF, Hsieh SM, Sheng WH, Chang SC.

AIDS. 2003 Dec 5;17(18):2615-22.

PMID:
14685055
[PubMed - indexed for MEDLINE]
10.

Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults.

Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L, Chaisson RE, Maartens G.

J Acquir Immune Defic Syndr. 2006 Sep;43(1):78-84.

PMID:
16878045
[PubMed - indexed for MEDLINE]
11.

Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.

Wong KH, Chan KC, Lee SS.

Clin Infect Dis. 2004 Sep 15;39(6):853-60. Epub 2004 Aug 27.

PMID:
15472819
[PubMed - indexed for MEDLINE]
Free Article
12.

Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa.

Barth RE, van der Meer JT, Hoepelman AI, Schrooders PA, van de Vijver DA, Geelen SP, Tempelman HA.

Eur J Clin Microbiol Infect Dis. 2008 Oct;27(10):977-84. doi: 10.1007/s10096-008-0534-2. Epub 2008 Jul 16.

PMID:
18629557
[PubMed - indexed for MEDLINE]
13.

The impact of malnutrition on survival and the CD4 count response in HIV-infected patients starting antiretroviral therapy.

Paton NI, Sangeetha S, Earnest A, Bellamy R.

HIV Med. 2006 Jul;7(5):323-30.

PMID:
16945078
[PubMed - indexed for MEDLINE]
14.

Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.

Etard JF, Ndiaye I, Thierry-Mieg M, Guèye NF, Guèye PM, Lanièce I, Dieng AB, Diouf A, Laurent C, Mboup S, Sow PS, Delaporte E.

AIDS. 2006 May 12;20(8):1181-9.

PMID:
16691070
[PubMed - indexed for MEDLINE]
15.

Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.

Hung CC, Chen MY, Hsieh SM, Hsiao CF, Sheng WH, Chang SC.

Vaccine. 2004 May 7;22(15-16):2006-12.

PMID:
15121313
[PubMed - indexed for MEDLINE]
16.

Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand.

Fregonese F, Collins IJ, Jourdain G, Lecoeur S, Cressey TR, Ngo-Giang-Houng N, Banchongkit S, Chutanunta A, Techapornroong M, Lallemant M; Program for HIV Prevention and Treatment Study Group.

J Acquir Immune Defic Syndr. 2012 May 1;60(1):91-8. doi: 10.1097/QAI.0b013e31824bd33f.

PMID:
22293548
[PubMed - indexed for MEDLINE]
17.

Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort.

Lawn SD, Badri M, Wood R.

AIDS. 2005 Dec 2;19(18):2109-16.

PMID:
16284460
[PubMed - indexed for MEDLINE]
18.

Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries.

Sow PS, Otieno LF, Bissagnene E, Kityo C, Bennink R, Clevenbergh P, Wit FW, Waalberg E, Rinke de Wit TF, Lange JM; Cohort Program to Evaluate Access to Antiretroviral Therapy and Education Project Team.

J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):262-7.

PMID:
17146376
[PubMed - indexed for MEDLINE]
19.

Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals.

Lohse N, Obel N, Kronborg G, Laursen A, Pedersen C, Larsen CS, Kvinesdal B, Sørensen HT, Gerstoft J.

AIDS. 2005 May 20;19(8):815-22.

PMID:
15867496
[PubMed - indexed for MEDLINE]
20.

Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation.

Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R.

Clin Infect Dis. 2006 Sep 15;43(6):770-6. Epub 2006 Aug 8.

PMID:
16912954
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk